Just reported
From Resmed's results release of 29 de octubre de 2026; its quarterly report has since been filed.
Actual
1,41B US$
+5,9 % y/y
-3,3 % q/q
Guided
—
No guide given
Actual
2,92 US$
+23 % y/y
+11 % q/q
Guided
—
No guide given
Actual
453M US$
+1,4 % y/y
+1,0 % q/q
Guided
—
No guide given
Full year 2027
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The themes Resmed is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Los porcentajes de ingresos son estimaciones para quarter ended 2026-03-31, no cifras de un informe oficial.
AirSense 11
A connected machine that delivers continuous or automatically adjusted air pressure to treat sleep apnea.
AirCurve 11
A bilevel breathing machine that provides different pressure levels for breathing in and out, for people needing more support or with complex breathing disorders.
Astral ventilators
Ventilators that provide breathing support, including for people receiving care at home.
AirTouch N30i, AirTouch F30i, and AirFit F40 masks
Masks that connect a person to a breathing machine during sleep; the named models include fabric and silicone designs.
myAir and AirView
Software for patients to engage with their sleep treatment and for providers to connect with and support patients.
Brightree and MEDIFOX DAN
Software products for residential care and home medical equipment providers.
Estados financieros completos →
ResMed makes devices that help people breathe during sleep and ventilators for people who need breathing support. It also sells masks and software for patients, medical equipment providers, and residential care providers. Its sleep products include machines that connect with patient and provider software.
Construido a partir de los propios informes de Resmed Inc. ante la Comisión de Bolsa y Valores de EE. UU. (SEC). Las cifras son las declaradas, con el historial por acción reexpresado a la base de acciones de hoy. Esto describe un negocio: no es asesoramiento de inversión ni una recomendación de compra o venta.
239,53 US$+0,2 %cierre 13 nov
Cifras hasta el 30 de septiembre de 2026, del 10-Q presentado el 30 de octubre de 2026
ResMed sells breathing machines and masks for sleep apnea and other breathing disorders to patients through medical equipment providers.
Grade B+
La franja bajo el precio muestra la calificación en cada fecha, calculada solo con los informes ya públicos en ese momento.
Mostrando 2 de 41 trimestres del historial de calificaciones de Resmed Inc.. Los otros 39 llegan hasta octubre de 2016.